Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. - Wikidata - wikimedia - TriplyDB

Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay.

Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay.

http://www.wikidata.org/entity/Q37002423

about

Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis Methotrexate for primary biliary cirrhosis Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy?Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014.Prospective comparison of magnetic resonance imaging to transient elastography and serum markers for liver fibrosis detection.Invasive and non-invasive diagnosis of cirrhosis and portal hypertension Comparison of accuracy of fibrosis degree classifications by liver biopsy and non-invasive tests in chronic hepatitis C Evolving therapies for liver fibrosis.Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B.Role of simple biomarkers in predicting fibrosis progression in HCV infection.Biopsy-controlled liver fibrosis staging using the enhanced liver fibrosis (ELF) score compared to transient elastography.Serum GP73, a marker for evaluating progression in patients with chronic HBV infections.Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection.The performance of enhanced liver fibrosis (ELF) test for the staging of liver fibrosis: a meta-analysis.Primary biliary cirrhosis and Sjögren's syndrome: autoimmune epithelitis.Risk factors for hepatic decompensation in patients with primary biliary cirrhosis Association of HIV, Hepatitis C Virus, and Liver Fibrosis Severity With the Enhanced Liver Fibrosis Score.Enhanced liver fibrosis marker as a noninvasive predictor of mortality in HIV/hepatitis C virus-coinfected women from a multicenter study of women with or at risk for HIV.Isolated Hepatitis B Core Antibody Status Is Not Associated With Accelerated Liver Disease Progression in HIV/Hepatitis C Coinfection Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.Natural history and management of primary biliary cirrhosis.Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challenge.Evaluation of the aspartate aminotransferase/platelet ratio index and enhanced liver fibrosis tests to detect significant fibrosis due to chronic hepatitis C.Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic.Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve?Mechanisms and biomarkers of apoptosis in liver disease and fibrosis.Molecular serum markers of liver fibrosis.Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies Review article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis.Non-invasive monitoring of liver fibrosis.Emerging drugs for the treatment of Primary Biliary Cholangitis.Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study.Enhanced liver fibrosis test in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross-sectional comparison with procollagen-3 N-terminal peptide (P3NP).Geoepidemiology and changing mortality in primary biliary cholangitis.Enhanced liver fibrosis test using ELISA assay accurately discriminates advanced stage of liver fibrosis as determined by transient elastography fibroscan in treatment naïve chronic HCV patients.Noninvasive methods for the assessment of liver fibrosis: a window open on the future?Noninvasive serum models to predict significant liver related events in chronic hepatitis C.Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study.Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein Level Predicts Liver Fibrosis and Prognosis in Primary Biliary Cirrhosis.

P2860

Q21261905-2A20DD68-2363-4082-B914-2900679206B3 Q24235442-47D1FEE7-D276-4251-BCED-C9A3FDA5034D Q26744631-D264FEC6-48BF-4EF5-A155-07992901D9DB Q26796355-6FF6E48D-FE4E-4024-8B26-C9A27DB78D16 Q28082065-5451B920-ECF3-4C7C-A07D-C328CCA977D8 Q30357769-BEC5124D-B8BE-4BBE-81A8-2D5587892C93 Q30439743-3DB9A09D-D18E-4352-BAF4-8D87EC9A01BC Q30471886-1EEEE201-C766-4A2C-AC50-01B235268B15 Q30539166-6684116C-4926-44A8-BE81-67D215879DE2 Q34359330-F448A3B2-B5CA-4C22-B321-0CBE9C5B2D7B Q34385138-354AE510-F0ED-4680-AB1E-8090921BBA91 Q34532528-29922582-F2DE-48E3-9D3B-F8DB397F9E48 Q34589487-7CFA5B54-9303-4544-9062-5488D5430875 Q34981143-CB7751B8-4C8D-4DE2-82D9-1987A978568F Q35149314-DD7CCCBE-9960-4039-8EE5-65810F32FBBA Q36599248-FB251FE9-8026-4176-ACCE-666CBCBAD293 Q36637728-D8533BCC-67CA-40C2-AE76-DFAD26D9877D Q36654566-13C9B602-0903-4E3E-8A39-7D46DC1E8E42 Q36715064-16327A23-4281-4B42-B9C4-A420AD431A9E Q37014002-D90498C7-FD89-4040-823E-446578F28402 Q37086216-55D891E6-F105-40FA-8F6B-365ACC8724E3 Q37355843-C6EB99EC-FAF8-4374-825A-76C78CF8E331 Q37584099-FBCB51CA-E54B-4B59-828C-4C5F6ADC27BC Q37627015-BE1C55CA-C314-4487-86A0-06EFB9DE76AC Q37825556-3EA3ECA9-30EC-4125-9488-33CCD9863B56 Q37897194-D4CF0C0B-7437-4FD9-B22B-2C5D0AFD2049 Q38008400-7F283ECD-0BF4-4EE8-8D93-F16FEB9D4642 Q38032835-E192AD79-2195-4D4D-B7B8-49534D2FC705 Q38073028-480E6184-6D4E-4A80-982E-EBCC0E2B2918 Q38175465-BD2836F5-4A66-4B52-8A3F-D6EB0221869B Q38262486-CC791FD7-87FA-47F3-8B1B-0B8AFD3DA457 Q38744215-0447DE85-AD3F-4B2D-9799-06C0D45FE612 Q38924675-2DD73377-52DF-44C3-A530-8A93793528EE Q39124718-4557A062-A9C3-4AAD-9F17-D15D448D263C Q39213467-3BC1C8D8-CC71-4D6E-B6DE-35ABD63A3EE8 Q39324556-A9CBA125-137F-4111-A7E0-9145C52588CF Q39702780-5DE52646-0C6B-453C-8642-950BC5E585EC Q40151847-DFF270D7-3177-4651-A021-2718D5F1FF38 Q40898741-A52B984F-7CAF-485E-A596-68C95B7F9D2A Q41009473-93AD6004-B6AE-4197-A35C-DCA832FFAFD2

P2860

Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay.

http://www.wikidata.org/entity/Q37002423

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Prediction of clinical outcome ...... enhanced liver fibrosis assay.

@en

Prediction of clinical outcome ...... enhanced liver fibrosis assay.

@nl

type

label

Prediction of clinical outcome ...... enhanced liver fibrosis assay.

@en

Prediction of clinical outcome ...... enhanced liver fibrosis assay.

@nl

prefLabel

Prediction of clinical outcome ...... enhanced liver fibrosis assay.

@en

Prediction of clinical outcome ...... enhanced liver fibrosis assay.

@nl

P1433

Q37002423-9A4094C3-F159-48C2-A999-60C034C5510B

P1476

Q37002423-0133D915-C72E-4482-A6F2-C2743436E976

P2093

Q37002423-1EAFD0CA-56FD-4C3A-8569-005A812DCF0D

Q37002423-32F4D0C7-6A4C-4DBA-A34B-2C26CDD7DEDD

Q37002423-38D00B9B-84B1-4636-AB74-516AB1E35C32

Q37002423-3CC9CDFA-E8FF-4094-BC79-CCF71BDF25BD

Q37002423-534FAC64-85A4-403E-A897-59B25FF2A1A8

Q37002423-62E9155A-1B33-4551-8AE0-859F72567508

Q37002423-646E590E-075C-49F3-BBED-2A2A9A8CF228

Q37002423-6789597A-A359-4310-B711-051023196159

Q37002423-718014D1-0D3E-4275-B4D8-88F104ED62D0

Q37002423-7AFD43B3-4F39-4504-8C42-AAA05100A314

P2860

Q37002423-0C75CAEC-C142-4512-87AF-D91DBD7EB7BB

Q37002423-21161C2C-FA05-461B-BA68-1192CBC8C356

Q37002423-368434EF-06E2-4637-97CF-73AB851DDEC0

Q37002423-370DC32F-6A71-49FE-B433-60E41AB026E9

Q37002423-74C10DDC-02B5-49DD-9689-806EE2B9F94F

Q37002423-78B17A48-059F-4908-8110-05E2B5CD012D

Q37002423-7C1FA72F-6C6B-4BE1-A4C2-6B0D4823B3D5

Q37002423-7CC62DEB-E046-4554-BF72-26BB84BF4304

Q37002423-7CFDE134-B30A-4111-AE20-533B323B76FB

Q37002423-87E06CC6-B6EB-4617-9721-A47BF38B679B

P304

Q37002423-28849532-50B0-4E37-8182-F90BAFDCD786

P31

Q37002423-6B173841-E981-4CF1-AA2D-0EB02BEC244E

P356

Q37002423-0605D5E7-7FD8-4793-B3CB-89C73162DFA1

P407

Q37002423-4FCF0243-F680-49F2-AE1B-B4078F34000C

P433

Q37002423-C96FEBC3-83D2-4E84-B91E-19AC21AF4BC0

P478

Q37002423-17DD35C2-5FEB-4488-B772-7EAF1CB5ABBB

P50

Q37002423-B07C5AA7-FECF-4F0C-BC54-032553B8C617

P577

Q37002423-3E2B96D6-0709-4317-8169-DC949A5B5581

P5875

Q37002423-48ED9A92-10B6-4CD5-BC30-5AEF6A51209E

P698

Q37002423-C2B275DF-34AD-40CB-81F7-F6DF749EEC83

P921

Q37002423-EB1B4AB6-F61C-4310-96EB-C56247093454

P932

Q37002423-C6D2DE42-B7CB-40FE-A471-BA7236C6C075

P356

P1433

P1476

Prediction of clinical outcome ...... enhanced liver fibrosis assay.

@en

P2093

A B West

http://www.w3.org/2001/XMLSchema#string

A S Mills

http://www.w3.org/2001/XMLSchema#string

Beverley Adams-Huet

http://www.w3.org/2001/XMLSchema#string

Burton Combes

http://www.w3.org/2001/XMLSchema#string

David Barnes

http://www.w3.org/2001/XMLSchema#string

Donald Wheeler

http://www.w3.org/2001/XMLSchema#string

Enrique Martinez

http://www.w3.org/2001/XMLSchema#string

Guadalupe Garcia-Tsao

http://www.w3.org/2001/XMLSchema#string

James Boyer

http://www.w3.org/2001/XMLSchema#string

John Lake

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease

Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers

Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach

Histological grading and staging of chronic hepatitis

A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C.

Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease.

Fibrosis as an end point for clinical trials in liver disease: a report of the international fibrosis group.

Accuracy of staging in primary biliary cirrhosis.

Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis).

Nonsuppurative destructive chronic cholangitis and chronic hepatitis.

P304

1549-1557

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.22517

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P50

Adrian M. Di Bisceglie

P577

2008-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23310828

http://www.w3.org/2001/XMLSchema#string

P698

18846542

http://www.w3.org/2001/XMLSchema#string

P921

liver cirrhosis

P932

2597274

http://www.w3.org/2001/XMLSchema#string